{"title":"Kynurenine amplifies tetrahydrocannabinol-induced sensorimotor impairment and classic “tetrad” effects in mice","authors":"Sabrine Bilel , Giorgia Corli , Edoardo Tiziani , Daniele Chirenti , Stefano Dall'Acqua , Stefano Comai , Luca Ferraro , Matteo Marti , Sarah Beggiato","doi":"10.1016/j.pnpbp.2025.111342","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>L-kynurenine (KYN), a kynurenine pathway (KP) metabolite, is the main precursor for the neuroactive metabolite kynurenic acid (KYNA). Several studies suggest a patho-physiologically relevant association between increased brain KYNA levels and cognitive dysfunctions in individuals with schizophrenia. Δ<sup>9</sup>-tetrahydrocannabinol (Δ<sup>9</sup>-THC; <em>i.e.</em> the main psychoactive compound of cannabis) can worse schizophrenia-related psychosis, often leads to the development of cannabis use disorder in individuals with schizophrenia, and increases the risk of earlier onset of schizophrenia symptoms in those with a genetic predisposition. A role of KP alterations and, specifically, increased brain KYNA levels in Δ<sup>9</sup>-THC-induced psychotic symptoms has been previously proposed. The aim of the study was to investigate on the possible involvement of KP alterations in Δ<sup>9</sup>-THC-induced sensorimotor and “tetrad” responses in mice.</div></div><div><h3>Methods</h3><div>Adult male CD-1 mice were treated with Δ<sup>9</sup>-THC (30 mg/ kg; i.p.) and KYN (20 mg/kg; i.p.), alone or in combination, and body temperature, acute mechanical and thermal analgesia, motor activity and sensorimotor responses were evaluated. Furthermore, brain KYNA levels as well as plasma Δ<sup>9</sup>-THC and its metabolites concentrations after the treatments were also evaluated.</div></div><div><h3>Results</h3><div>Brain KYNA levels were significantly increased 1 h, but not 4 h, after KYN and KYN + Δ<sup>9</sup>-THC administration. KYN administration amplified the Δ<sup>9</sup>-THC-induced impairment of sensorimotor responses (visual placing, acoustic and tactile responses). Furthermore, KYN significantly increased Δ<sup>9</sup>-THC-induced motor activity impairment (bar test, drag test and rotarod test) and hypothermia (core and surface body temperature), but not Δ<sup>9</sup>-THC-induced analgesia. Finally, 1 h after Δ<sup>9</sup>-THC administration, Δ<sup>9</sup>-THC and its psychoactive metabolite 11-OH-THC plasma levels were higher in mice pretreated with KYN than in control mice.</div></div><div><h3>Conclusions</h3><div>The present data indicate for the first time that KYN amplifies the THC-induced sensorimotor impairment and classic “tetrad” response possibly through a pharmacokinetic interaction.</div></div>","PeriodicalId":54549,"journal":{"name":"Progress in Neuro-Psychopharmacology & Biological Psychiatry","volume":"138 ","pages":"Article 111342"},"PeriodicalIF":5.3000,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Progress in Neuro-Psychopharmacology & Biological Psychiatry","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S027858462500096X","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background
L-kynurenine (KYN), a kynurenine pathway (KP) metabolite, is the main precursor for the neuroactive metabolite kynurenic acid (KYNA). Several studies suggest a patho-physiologically relevant association between increased brain KYNA levels and cognitive dysfunctions in individuals with schizophrenia. Δ9-tetrahydrocannabinol (Δ9-THC; i.e. the main psychoactive compound of cannabis) can worse schizophrenia-related psychosis, often leads to the development of cannabis use disorder in individuals with schizophrenia, and increases the risk of earlier onset of schizophrenia symptoms in those with a genetic predisposition. A role of KP alterations and, specifically, increased brain KYNA levels in Δ9-THC-induced psychotic symptoms has been previously proposed. The aim of the study was to investigate on the possible involvement of KP alterations in Δ9-THC-induced sensorimotor and “tetrad” responses in mice.
Methods
Adult male CD-1 mice were treated with Δ9-THC (30 mg/ kg; i.p.) and KYN (20 mg/kg; i.p.), alone or in combination, and body temperature, acute mechanical and thermal analgesia, motor activity and sensorimotor responses were evaluated. Furthermore, brain KYNA levels as well as plasma Δ9-THC and its metabolites concentrations after the treatments were also evaluated.
Results
Brain KYNA levels were significantly increased 1 h, but not 4 h, after KYN and KYN + Δ9-THC administration. KYN administration amplified the Δ9-THC-induced impairment of sensorimotor responses (visual placing, acoustic and tactile responses). Furthermore, KYN significantly increased Δ9-THC-induced motor activity impairment (bar test, drag test and rotarod test) and hypothermia (core and surface body temperature), but not Δ9-THC-induced analgesia. Finally, 1 h after Δ9-THC administration, Δ9-THC and its psychoactive metabolite 11-OH-THC plasma levels were higher in mice pretreated with KYN than in control mice.
Conclusions
The present data indicate for the first time that KYN amplifies the THC-induced sensorimotor impairment and classic “tetrad” response possibly through a pharmacokinetic interaction.
期刊介绍:
Progress in Neuro-Psychopharmacology & Biological Psychiatry is an international and multidisciplinary journal which aims to ensure the rapid publication of authoritative reviews and research papers dealing with experimental and clinical aspects of neuro-psychopharmacology and biological psychiatry. Issues of the journal are regularly devoted wholly in or in part to a topical subject.
Progress in Neuro-Psychopharmacology & Biological Psychiatry does not publish work on the actions of biological extracts unless the pharmacological active molecular substrate and/or specific receptor binding properties of the extract compounds are elucidated.